Education
About Us
Working with TipRanks
Follow Us
Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
ALLR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.61 - $6.03
Previous CloseN/A
Volume542.33K
Average Volume (3M)433.11K
Market Cap
$14.45M
Enterprise Value-$9.64M
Total Cash (Recent Filing)$25.20M
Total Debt (Recent Filing)$1.36M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Nov 12, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding15,079,572
10 Day Avg. Volume226,711
30 Day Avg. Volume433,110
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.64K
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$9.00Price Target Upside837.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Allarity Therapeutics News
ALLR FAQ
What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.61 and its highest was $6.03 in the past 12 months.
What is Allarity Therapeutics, Inc.’s market cap?
Allarity Therapeutics, Inc.’s market cap is $14.45M.
When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
Allarity Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 84 days.
How were Allarity Therapeutics, Inc.’s earnings last quarter?
Allarity Therapeutics, Inc. released its earnings results on Aug 15, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.21 by $0.06.
Is Allarity Therapeutics, Inc. overvalued?
According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Undervalued.
Does Allarity Therapeutics, Inc. pay dividends?
Allarity Therapeutics, Inc. does not currently pay dividends.
What is Allarity Therapeutics, Inc.’s EPS estimate?
Allarity Therapeutics, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Allarity Therapeutics, Inc. have?
Allarity Therapeutics, Inc. has 15,079,572 shares outstanding.
What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
Allarity Therapeutics, Inc. reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.21. Following the earnings report the stock price went down -5.208%.
Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALLR
Company Description
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
ALLR Stock 12 Month Forecast
Average Price Target
$9.00
▲(837.50% Upside)
Technical Analysis
Ownership Overview
4.94% Insiders
0.07% Mutual Funds
0.13% Other Institutional Investors
94.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---